Kangrui Biotech

Kangrui Biotech is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation targeted therapies for the RAS signaling pathway. Founded in 2021 by Dr. Huijun (Willy) Sun, a former R&D leader at Hengrui Pharmaceutical, the company specializes in small molecule inhibitors for traditionally "undruggable" oncology targets. Its lead program is a highly selective KRAS G12D inhibitor currently undergoing Phase 1 clinical trials for patients with advanced solid tumors, including pancreatic and colorectal cancers. Headquartered in Suzhou's BioBay, Kangrui Biotech leverages a deep understanding of RAS biology to build a comprehensive pipeline that includes G12C, G12D, and pan-RAS inhibitors. The company is backed by prominent venture capital firms, including Matrix Partners China and Qiming Venture Partners.